Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: acomplia + 0.34 + medicines  Related to the article below (Last Update: 8/5/2008)

MIMS Summary: NICE approves Acomplia
Healthcare Republic (press release), UK - Jul 29, 2008
NICE has issued final guidance on the use of rimonabant (Acomplia) for the treatment of obesity. Rimonabant is recommended as an adjunct to diet and ...
French Health Authority Modifies Acomplia Medical Notice
EasyBourse.com, France - Jul 11, 2008
... The French health authority Afssaps said Friday it has modified the summary of characteristics of the Sanofi-Aventis (SNY) marketed drug Acomplia. ...SNY
Weeding Out The Highs Of Medical Marijuana
Science Daily (press release) - Jul 14, 2008
But my research group has discovered that another constituent of cannabis, THCV, acts in a similar way to Acomplia, blocking one of the cannabinoid ...
Drug Marketing Poised For Historic Decline
Brandweek Magazine, NY - Jul 29, 2008
Novartis had backed Zelnorm with $90 million, and Acomplia was expected to be a huge launch. ? Drug companies' R&D pipelines won't fill up the gaps until ...
Supersized Problems
Financial Times, UK - Jul 19, 2008
Rimonabant, known by the brand name Acomplia, joins orlistat (Xenical) and sibutramine (Reductil) in the range of weight-loss drugs available from doctors ...
Sanofi-aventis News
PR Newswire (press release), NY - Jul 31, 2008
Net sales of Acomplia(R) reached euro 32 million in the second quarter and euro 54 million in the first half. During the second quarter, Acomplia(R) was ...SNY
Sanofi-aventis News
PharmaLive.com (press release), PA - Jul 31, 2008
Net sales of Acomplia(R) reached euro 32 million in the second quarter and euro 54 million in the first half. During the second quarter, Acomplia(R) was ...SNY
HEARD ON THE STREET
Wall Street Journal - Jul 31, 2008
The failings of Acomplia, an obesity treatment, and antibiotic Ketek are well-documented. Hypertension treatment Delix is a cardiovascular also-ran. ...
Drug Makers Seek Antiobesity Blockbuster
Wall Street Journal - Jul 28, 2008
Acomplia, a weight-loss pill from France's Sanofi-Aventis SA, was refused marketing approval by the US Food and Drug Administration in 2007 after reports of ...
Discover the Next Generation Treatments and Market Dynamics with ...
MarketWatch - Jul 18, 2008
Sanofi-Aventis' Acomplia (rimonabant) is a first-in-class CB-1 antagonist indicated for the treatment of overweight patients with associated Type 2 diabetes ...
Source: Google News

Pharmacotherapy as Part of a Weight Management Programme: A UK Perspective -
L In, PEM Data, H Supplements, K Messages - medscape.com
... 8] Data from meta-analyses show an average decrease in systolic and diastolic BP
of 0.68 and 0.34 mmHg, respectively ... Acomplia Summary of Product Characteristics ...
-

[PDF] Pharmacotherapy as part of a weight management programme: a UK perspective
AH BARNETT - Br J Diabetes Vasc Dis, 2007 - bjdvd.com
... Data from meta-analyses show an average decrease in systolic and diastolic BP of
0.68 and 0.34 mmHg, respectively, with each 1 kg of weight loss, 9 and a ...

IN THIS ARTICLE -
AO Coffay - UPDATE, 2008 - obgmanagement.com
... Buspirone 23, 0.71 (0.34?1.48), 201/3, 22.1, $280/$84. ... 28 The initial studies of
rimonabant (Acomplia), a cannabinoid blocker, have shown that it is no better ...

[PDF] Smoking cessation: Tactics that make a difference
CS who uses OCs - obgmanagement.com
... Diazepam 23 1.00 (0.39?2.54) 76/1 No $209/$27 difference SSRI 15 0.90 (0.68?1.18)
1,768/6 20.7 $170/$4 Buspirone 23 0.71 (0.34?1.48) 201/3 22.1 $280/$84 ...

[PDF] Current knowledge on the antagonists and inverse agonists of cannabinoid receptors -
GG Muccioli, DM Lambert - Curr. Med. Chem, 2005 - farm.ucl.ac.be
... 9 -THC), the analgesic effect of ? 9 -THC containing cannabis preparations [26],
or in contrast, for the anti-obesity effect of rimonabant (Acomplia ? ). ...

Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor … -
KS Song, SH Lee, HJ Chun, JY Kim, ME Jung, K Ahn, … - Bioorganic & Medicinal Chemistry, 2008 - Elsevier
... 17 Even though rimonabant (Acomplia TM ) is currently launched by Sanofi-Aventis
in the ... purified by prep HPLC to yield the title compound (141 mg, 0.34 mmol, 43 ...

[PDF] CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation … -
G Parenty, S Appelbe, G Milligan - Biochem J, 2008 - biochemj.org
... Co-expression of h-DOP-Renilla luciferase with h-CXCR2-GFP 2 generated BRET signals
that saturated, and in this case BRET 50 was 0.34 +/- 0.02 (Figure 2C). ...

6 Recent Progress in Cannabinoid Research -
J ADAM, PM COWLEY, T KIYOI, AJ MORRISON, CJW MORT - Progress in Medicinal Chemistry, 2006 - books.google.com
... 0. 17 0.14 0.27 0.03 0.04 0.45 0.12 0.39 0.24 2.1 b TF > 100 25 10 1.9 4.8 1.5 4.8
2.1 6.1 5.2 1.2 1.0 0.4 1.8 0.21 0.61 0.14 0.03 0.10 0.42 0.18 0.34 0.30 5.1 ...

[PDF] Pharmacological Analysis of Cannabinoid Receptor Activity in Isolated Nerve-Smooth Muscle and …
R Makwana - 2007 - uhra.herts.ac.uk
Page 1. PHARMACOLOGICAL ANALYSIS OF CANNABINOID RECEPTOR ACTIVITY IN ISOLATED
NERVE-SMOOTH MUSCLE AND EPITHELIAL PREPARATIONS RAJESH MAKWANA, B.Sc. ...

4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES -
E Martinez, JJ Talley, S Antonelli, TC Barden, R … - EP Patent 1,682,499, 2007 - freepatentsonline.com
... teucrium chamaedrys), B-hydroxy-?-methylbutyrate, ATL-962 (Alizyme PLC), T71 (Tularik,
Inc.; Boulder CO), a ghrelin antagonist, Acomplia (rimonabant), AOD9604 ...
-

Source: Google Scholar

European Medicines Agency Recommends Acomplia Must Not Be Used In Patients On Antidepressants Or With Major Depression
The European Medicines Agency (EMEA) recommended contraindicating Acomplia (rimonabant) from sanofi-aventis, in patients with ongoing major depression or who are being treated with antidepressants, because of the risk of psychiatric side effects. Doctors in the EU have already been warned about this since June 2006 but the Agency's Committee for Medicinal Products for Human Use (CHMP) has now recommended upgrading this warning.

Acomplia has been authorised in the EU since June 2006 as an adjunct to diet and exercise for the treatment of obese or overweight adult patients. Psychiatric side effects, in particular depression, were identified as the main safety issue at the time of approval. They were reflected in the medicine's product information as a warning that doctors should not prescribe Acomplia in patients with uncontrolled serious psychiatric conditions such as major depression.
As part of its continuous monitoring of the safety of medicines, the CHMP requested sanofi-aventis in June 2007 to submit all available information on the psychiatric side effects of Acomplia. Finalising the assessment of the available data at its 16-19 July 2007 meeting, the CHMP concluded that the benefits of Acomplia continue to outweigh its risks, except in patients with ongoing major depression or taking antidepressants.

The CHMP also recommended adding a warning that treatment with Acomplia should be stopped if a patient develops depression, as well as the inclusion of additional information on the psychiatric safety of Acomplia.

Doctors will be sent a letter to inform them about the updated prescribing information. Patients and their carers should be aware of the risk of depression in patients taking Acomplia.

The CHMP recommendation will now be forwarded to the European Commission for adoption of a Decision.

1. For more information, see the accompanying question-and-answer document , which also includes the recommended updated product information (in Annex 1).

2. Acomplia is authorised in the European Union/European Economic Area, and is marketed in 13 European countries. Rimonabant is also authorised as Zimulti, but this product is not marketed in the European Union.

3. The European Public Assessment Report for Acomplia can be found here.

4. This press release, together with other information on the work of the EMEA, can be found on the EMEA website: http://www.emea.europa.eu.
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
ALL THE NEWS : News1 ; News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.